Fig. 2From: Long-term outcomes with HLX01 (HanliKang®), a rituximab biosimilar, in previously untreated patients with diffuse large B-cell lymphoma: 5-year follow-up results of the phase 3 HLX01-NHL03 studyKaplan–Meier estimates of overall survival in (A) the overall population, (B) patients who completed six cycles of treatment, (C) patients with an IPI score of 1, and (D) patients with an IPI score of 2Back to article page